Starting 2024 with a positive EBITDA
Q1 2024 highlights
› Total net revenues of
› EBITDA of
› Net earnings of
› US Commercial segment net revenues of
› Cash flow from operating activities of
› Earnings per share before and after dilution amounted to
› MODIA® and Vorvida® were reimbursed within the US Veterans Affairs Federal Supply Schedule as of January 1, 2024
› Data from the clinical phase 1 study and stability data for OX640, a nasal epinephrine powder product, were presented at the
›
› To refinance the existing bond a four year senior secured social bond of
› The new bond was classified as a social bond after a social financing framework was established, which underwent an independent review by Morningstar Sustainalytics.
Important events after the end of the period
› Second patent in the US granted for OX640.
SEK m unless otherwise stated | 2024 Jan-Mar | 2023 Jan-Mar | 2023 Jan-Dec |
Net revenues | 139.3 | 158.8 | 638.8 |
Cost of goods sold | -13.3 | -28.7 | -88.9 |
Operating expenses | -130.7 | -189.4 | -659.5 |
EBIT | -4.7 | -59.3 | -109.5 |
EBIT margin | -3.4% | -37.4% | -17.1% |
EBITDA | 15.9 | -41.1 | -32.5 |
Earnings per share. before dilution. SEK | -0.26 | -1.86 | -3.73 |
Earnings per share. after dilution. SEK | -0.26 | -1.86 | -3.73 |
Cash flow from operating activities | -18.9 | -61.6 | -95.0 |
Cash and invested funds | 198.0 | 278.9 | 171.0 |
CEO Comments in brief: Creating a stable financial platform
I am pleased to report a significant improvement in our financial results with an EBITDA increasing
For the full CEO Comments read the PDF
Contact persons quarterly report
Presentation
On
To attend via teleconference where you can ask questions verbally:
https://conference.financialhearings.com/teleconference/?id=50048736
When registered you will be provided phone numbers and a conference ID to access the conference.
To attend via webcast:
https://ir.financialhearings.com/orexo-q1-report-2024
Prior to the call, presentation material will be available on the website under Investors/ Reports/Audiocasts.
This information is information that
https://news.cision.com/orexo/r/orexo-q1-2024-interim-report,c3975281
https://mb.cision.com/Main/694/3975281/2784543.pdf
(c) 2024 Cision. All rights reserved., source